Cite
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
MLA
Duffaud, Florence, et al. “Efficacy and Safety of Regorafenib in Patients with Metastatic or Locally Advanced Chondrosarcoma: Results of a Non-Comparative, Randomised, Double-Blind, Placebo Controlled, Multicentre Phase II Study.” European Journal of Cancer (Oxford, England : 1990), vol. 150, June 2021, pp. 108–18. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.03.039.
APA
Duffaud, F., Italiano, A., Bompas, E., Rios, M., Penel, N., Mir, O., Piperno-Neumann, S., Chevreau, C., Delcambre, C., Bertucci, F., Boudou-Rouquette, P., Cancel, M., Perrin, C., Saada-Bouzid, E., Monard, L., Schiffler, C., Chaigneau, L., Hervieu, A., Collard, O., … Blay, J.-Y. (2021). Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. European Journal of Cancer (Oxford, England : 1990), 150, 108–118. https://doi.org/10.1016/j.ejca.2021.03.039
Chicago
Duffaud, Florence, Antoine Italiano, Emannuelle Bompas, Maria Rios, Nicolas Penel, Olivier Mir, Sophie Piperno-Neumann, et al. 2021. “Efficacy and Safety of Regorafenib in Patients with Metastatic or Locally Advanced Chondrosarcoma: Results of a Non-Comparative, Randomised, Double-Blind, Placebo Controlled, Multicentre Phase II Study.” European Journal of Cancer (Oxford, England : 1990) 150 (June): 108–18. doi:10.1016/j.ejca.2021.03.039.